Patients with Malignant Hyperthermia Demonstrate an Altered Calcium Control Mechanism in B Lymphocytes

Background Altered Ca2+ homeostasis in skeletal muscle is a key molecular event triggering malignant hyperthermia (MH) in malignant hyperthermia-susceptible (MHS) individuals. Genetic studies have shown that mutations in the type 1 ryanodine receptor (RYR1) are associated with MH susceptibility. Because human B lymphocytes express the RYR1, it is hypothesized that Ca2+ homeostasis in B lymphocytes is altered in MHS individuals. Methods This study investigated the Ca2+ response of B cells to caffeine and 4-chloro-m-cresol in 13 MHS and 21 MH-negative (MHN) individuals who had been diagnosed by caffeine halothane contracture test (CHCT) and 18 healthy volunteers. Changes in [Ca2+]i in B cells were measured directly in fluo-3 loaded cells using a dual-color flow cytometric technique. Further, B cell phenotype was correlated with CHCT results in a family with the Val2168Met (G6502A) mutation. Results Caffeine-induced (50 mm) increases in [Ca2+]i in B cells were significantly greater in MHS than in MHN (P = 0.0004), control (P = 0.0001) or non-MHS (MHN and control) individuals (P < 0.0001). The 4-chloro-m-cresol-induced (400 &mgr;m) increases in [Ca2+]i were also significantly different between MHS and controls (P = 0.003) or between MHS and non-MHS (MHN and control) individuals (P = 0.0078). A study of a family with the Val2168Met mutation demonstrated expression of the RYR1 mRNA mutant in B cells from the family members with MHS phenotype and a clear segregation of genotype with B-cell phenotype. Conclusion The Ca2+ responses to caffeine or 4-chloro-m-cresol in B lymphocytes showed significant differences between MHS and MHN (or control) individuals. Although the molecular mechanisms of these alterations are currently undetermined, the results suggest that the enhanced Ca2+ responses are associated with mutations in the RYR1 gene in some MHS individuals.

[1]  Beverley McNeil,et al.  Malignant Hyperthermia , 2005, Springer US.

[2]  Y. Matsuo,et al.  Expression of the Ryanodine Receptor Isoforms in Immune Cells1 , 2001, The Journal of Immunology.

[3]  T. Nelson,et al.  North American Malignant Hyperthermia Population: Screening of the Ryanodine Receptor Gene and Identification of Novel Mutations , 2001, Anesthesiology.

[4]  J. Daly,et al.  Multiple effects of caffeine on Ca2+ release and influx in human B lymphocytes. , 2001, Cell calcium.

[5]  S. Muallem,et al.  Gating of store-operated channels by conformational coupling to ryanodine receptors. , 2000, Molecular cell.

[6]  T. McCarthy,et al.  Ryanodine receptor mutations in malignant hyperthermia and central core disease , 2000, Human mutation.

[7]  M. Georgieff,et al.  A Multicenter Study of 4-Chloro-m-cresol for Diagnosing Malignant Hyperthermia Susceptibility , 2000, Anesthesia and analgesia.

[8]  A. Basile,et al.  Skeletal Muscle Type Ryanodine Receptor Is Involved in Calcium Signaling in Human B Lymphocytes* , 1999, The Journal of Biological Chemistry.

[9]  V. Sorrentino,et al.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families , 1999, Journal of medical genetics.

[10]  Gregory C. Allen,et al.  The Sensitivity and Specificity of the Caffeine-Halothane Contracture Test A Report from the North American Malignant Hyperthermia Registry , 1998 .

[11]  M. Berridge,et al.  Ca2+ entry into PC12 cells initiated by ryanodine receptors or inositol 1,4,5-trisphosphate receptors. , 1998, The Biochemical journal.

[12]  S. Grinstein,et al.  Caffeine and Halothane Sensitivity of Intracellular Ca2+ Release Is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations Associated with Malignant Hyperthermia and/or Central Core Disease* , 1997, The Journal of Biological Chemistry.

[13]  J. Mickelson,et al.  Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. , 1996, Physiological reviews.

[14]  E. Clementi,et al.  Chlorocresol: an activator of ryanodine receptor-mediated Ca2+ release. , 1993, Molecular pharmacology.

[15]  P. Arora,et al.  Quantitative analysis of calcium (Ca2+) mobilization after stimulation with mitogens or anti-CD3 antibodies. Simultaneous fluo-3 and immunofluorescence flow cytometry. , 1991, Journal of immunological methods.

[16]  Y. J. Lin,et al.  Caffeine‐Sensitive Calcium Stores in Bovine Adrenal Chromaffin Cells , 1991, Journal of neurochemistry.

[17]  M. G. Larach.  Standardization of the Caffeine Halothane Muscle Contracture Test , 1989, Anesthesia and analgesia.

[18]  J. Heffron.  Malignant hyperthermia: biochemical aspects of the acute episode. , 1988, British journal of anaesthesia.

[19]  H. Rosenberg.  Clinical presentation of malignant hyperthermia. , 1988, British journal of anaesthesia.

[20]  T. Nelson,et al.  The Malignant Hyperthermia Syndrome , 1983 .

[21]  G. Comi,et al.  Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia , 1998, Human mutation.

[22]  T. Nelson,et al.  Current concepts. The malignant hyperthermia syndrome. , 1983, The New England journal of medicine.